Legal Considerations in Commercializing Gene-Edited Plants: IP Protection, Licensing, Regulatory, and Compliance Issues
Berkeley Center for Law & Technology and Morrison & Foerster LLP
Legal Considerations in Commercializing Gene-Edited Plants: IP Protection, Licensing, Regulatory, and Compliance Issues
Berkeley Center for Law & Technology and Morrison & Foerster LLP
Over 130 attendees worldwide attended our two-day seminar on Legal Considerations in Commercializing Gene-Edited Plants where we took attendees through a real world hypothetical explaining the use of gene editing in plant breeding. We covered the science behind gene-editing technology as well as the related IP, licensing, regulatory and compliance issues.
Gene editing has the potential to revolutionize agriculture and food production. However, to be successful, innovators need to address the challenges of IP protection and licensing as well as regulatory hurdles in order to successfully commercialize a product. Day one of this two-part webinar took attendees through a real world hypothetical that explained the use of gene editing in agriculture and we discussed freedom-to-operate and licensing issues for edited plants. On day two, we took a deep dive into the IP protection for edited plants and commercialization requirements for edited plants and food products through a discussion of CRISPR licenses, FDA, USDA, and EPA regulatory approvals and other commercialization issues.
Day 1: Tuesday, June 8, 12:00 – 1:00 p.m. PDT
Day 2: Wednesday, June 9, 12:00 – 1:00 p.m. PDT
Supplemental materials can also be found on our life sciences blog and Food + Ag capabilities.